Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Pregnancy-related acute kidney injury (PRAKI) represents a significant cause of maternal and fetal morbidity. Early diagnosis is often hindered by physiological renal adaptations of pregnancy that mask serum creatinine elevations. The urinary biomarkers Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) and Insulin-like Growth Factor Binding Protein-7 (IGFBP7) have been proposed as early indicators of tubular stress preceding functional decline.
A prospective observational study was conducted from July 2024 to June 2025 at PGIMER, Chandigarh. Two hundred and three parturients with preeclampsia/eclampsia and twenty-five healthy controls were enrolled. Urinary TIMP-2 and IGFBP-7 were measured via ELISA at admission, 24 h, and 48 h. AKI was defined per KDIGO criteria. Statistical analyses included ANOVA, Chi-square, and ROC curve evaluation using IBM SPSS v23.
The incidence of AKI was 21.2%. Severe preeclampsia was strongly associated with AKI (67.4 % vs 41.8 %; p = 0.001). Urinary TIMP-2, IGFBP7, and their product were significantly elevated in AKI versus non-AKI and controls (p < 0.001). At a cutoff ≥ 0.938 ng/mL²/10³, [TIMP-2]*[IGFBP7] achieved an AUROC = 0.904 (95 % CI 0.845–0.963), sensitivity 88.4 %, specificity 88.7 %, PPV 67.9 %, NPV 96.6 %. Biomarker elevation preceded serum creatinine rise by 24–48 h. Three patients required renal replacement therapy; one death occurred due to multiorgan failure.
Urinary TIMP-2 and IGFBP7 provide sensitive and specific early detection of AKI in preeclamptic pregnancies. The [TIMP-2]*[IGFBP7] product ≥ 0.938 ng/mL²/10³ identifies women at high risk for PRAKI well before conventional markers rise, supporting early nephroprotective intervention.
